|
|
VBL Therapeutics is developing therapies targeting the vascular wall with a focus on cardiovascular and cancer applications. The company has identified an oral anti-inflammatory drug targeted toward inflammation associated with atherosclerosis. A second candidate is a therapy that leads to destruction of tumors through targeted angiogenesis.
Funders:
TEVA Pharmaceuticals
|
|
|